This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Adeona Executes WellZin™ Manufacturing And Supply Agreement

ANN ARBOR, Mich., Nov. 7, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), announced today that it has executed an agreement with F&F Foods of Chicago, Illinois, to provide commercial-scale manufacturing of wellZin™, the Company's oral zinc lozenge to reduce the duration and symptoms of the common cold. Adeona is planning to commercialize wellZin, a lozenge that contains 13.3 mg of zinc acetate, based on formulations clinically tested by Ananda S. Prasad, M.D., Ph.D., a Distinguished Professor of Internal Medicine at Wayne State University School of Medicine and an Adeona Scientific Advisory Board member. wellZin is intended to be a natural, safe and effective homeopathic over-the-counter (OTC) medicine for the common cold.

In July 2011, Adeona obtained exclusive access to statistically significant clinical data from two separate studies conducted by Dr. Prasad that evaluated the effectiveness of zinc acetate lozenges on the reduction of the duration and the symptoms of the common cold. Based upon findings from Dr. Prasad's two clinical studies[i],[ii] and his expertise as a pioneer in the field of zinc, he believes that many of the zinc preparations currently available on the market include a sub-optimal formulation and/or dose of zinc, and also include flavors and binders that diminish the effectiveness of zinc treatment for the common cold. In a February 15, 2011, New York Times article that referred to the recently published Cochrane Review of zinc for the common cold, Dr. Prasad was quoted as saying, "The public is confused because people have used the wrong dose, they have used the wrong sort of zinc or they have not started the treatment within 24 hours of onset."

"I am so excited to make wellZin commercially available for adults suffering from the symptoms of the common cold. When I notice cold symptoms coming on, it is the worst feeling and wellZin has the potential to cut the duration and the severity of symptoms of the common cold in half if you start taking it right away," stated James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer. "That is why executing this agreement with F&F Foods for the manufacturing of wellZin is so important – it brings us one step for closer to commercialization."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.57 -3.30%
FB $116.54 7.00%
GOOG $690.14 -2.20%
TSLA $248.50 -1.20%
YHOO $36.57 -1.00%


Chart of I:DJI
DOW 17,816.20 -225.35 -1.25%
S&P 500 2,076.57 -18.58 -0.89%
NASDAQ 4,810.8720 -52.2690 -1.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs